Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - MicardisPlus(R) - Hypertonie (38 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 27: Hypertonie - Bewußtsein Abb. 28: Morgendlicher Blutdruck Abb. 29: Blutdrucksenkung - Through/Peak-Ratio Aktuelles Bild - Abb. 30: Hypertonie - Behandlung Abb. 31: Hypertonie - Behandlung Abb. 32: Antihypertensiva - Nebenwirkung Abb. 33: Hypertonie - Behandlung Zum letzten Bild
Abbildung 30: Hypertonie - Behandlung
Failure to achieve target blood pressure can also result when patients do not adhere to their treatment regimen. One reason for non-adherence is multiple daily dosing. This meta-analysis of 8 studies shows that adherence to a once-daily dosing regimen is significantly greater than that to a twice-daily or multiple-daily dosing regimen.1 1. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24: 302–316.
 
Hypertonie - Behandlung
Vorheriges Bild Nächstes Bild   


Abbildung 30: Hypertonie - Behandlung
Failure to achieve target blood pressure can also result when patients do not adhere to their treatment regimen. One reason for non-adherence is multiple daily dosing. This meta-analysis of 8 studies shows that adherence to a once-daily dosing regimen is significantly greater than that to a twice-daily or multiple-daily dosing regimen.1 1. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24: 302–316.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung